Hepatitis B en pacientes con infección por el virus de la inmunodeficiencia humana

[1]  V. Soriano,et al.  Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. , 2008, AIDS.

[2]  C. Yurdaydın,et al.  A Novel Mutation Pattern Emerging during Lamivudine Treatment Shows Cross-Resistance to Adefovir Dipivoxil Treatment , 2007, Antiviral therapy.

[3]  Lin Shen,et al.  The HBV drug entecavir - effects on HIV-1 replication and resistance. , 2007, The New England journal of medicine.

[4]  V. Soriano,et al.  Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients , 2007, Journal of acquired immune deficiency syndromes.

[5]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[6]  V. Johnson,et al.  Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127 , 2006, Hepatology.

[7]  Ting Chang,et al.  Hepatitis B virus with primary resistance to adefovir [11] , 2006 .

[8]  M. Alter,et al.  A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States , 2006, Pediatrics.

[9]  M. Helm,et al.  Variant of hepatitis B virus with primary resistance to adefovir. , 2006, The New England journal of medicine.

[10]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[11]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[12]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[13]  C. Katlama,et al.  Anti‐hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV‐infected patients , 2006, Hepatology.

[14]  E. Keeffe,et al.  Hepatitis B vaccines. , 2006, Infectious disease clinics of North America.

[15]  M. Washington,et al.  A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. , 2006, Archives of internal medicine.

[16]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[17]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. , 2006, Journal of hepatology.

[18]  B. Rodés,et al.  Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir , 2005, AIDS.

[19]  W. Powderly,et al.  Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  N. Leung,et al.  A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.

[21]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[22]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[23]  Giorgio Palù,et al.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.

[24]  A. Barone,et al.  Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. , 2005, Vaccine.

[25]  V. Soriano,et al.  Erratum: Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel (AIDS (2005) 19 (221-240)) , 2005 .

[26]  V. Wong,et al.  A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.

[27]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[28]  R. Kaiser,et al.  Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment , 2004, AIDS (London).

[29]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[30]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[31]  D. Cooper,et al.  Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. , 2004, The Journal of infectious diseases.

[32]  C. Tural,et al.  Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations , 2004, Journal of viral hepatitis.

[33]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[34]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[35]  H. Lee,et al.  Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. , 2003, Journal of hepatology.

[36]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[37]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[38]  V. Soriano,et al.  Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. , 2003, AIDS research and human retroviruses.

[39]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[40]  M. Lai,et al.  Treatment with peginterferon alfa-2a (40KD) (PEGASYS®) results in improved rates of response compared to conventional interferon in patients with HBEAG positive chronic hepatitis B harboring HBV genotypes B or ‘difficult-to-treat’ genotype C , 2003 .

[41]  B. Gazzard,et al.  An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals , 2003, AIDS.

[42]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[43]  P. Tebas,et al.  Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. , 2002, The Journal of infectious diseases.

[44]  P. Marcellin,et al.  Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. , 2002, Gastroenterology.

[45]  V. Soriano,et al.  Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. , 2002, AIDS.

[46]  T. Berg,et al.  Tenofovir treatment in patients with lamivudine‐resistant hepatitis B mutants strongly affects viral replication , 2002, Hepatology.

[47]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[48]  M. Sterneck,et al.  Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[50]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[51]  R. Bruno,et al.  YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. , 2001, Gastroenterology.

[52]  F. Raffi,et al.  Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[54]  D. Cooper,et al.  Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. , 1999, The Journal of infectious diseases.

[55]  S. Lawrence,et al.  Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[57]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.